Basket

Record was added to the basket

1.Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies / Salek T. ... [et al.] . Onkológia. - ISSN 1336-8176 . - Roč. 17, č. 2 (2022), s. 139

C 3069
Request a copy DDS
DSD service
From the basket
Citation
Bookmark

Selected documents
Citation

citace PRO
article

For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.